

ECS Botanics Holdings Ltd (ASX:ECS)



ASX Announcement

7 October 2026

ECS Expands Branded Portfolio into United Kingdom in partnership with Curaleaf Laboratories

Highlights:

- ECS signs Distribution and Manufacturing Agreement with Curaleaf Laboratories, for the distribution of ECS-branded medicinal cannabis products in the United Kingdom
- Initial portfolio comprises six ECS-branded Australian-grown medicinal cannabis flower products, extending ECS's branded product strategy into the UK market
- ECS will supply Australian-grown medicinal cannabis flower in bulk, with Curaleaf Laboratories undertaking local manufacturing into patient-friendly pouches and distribution through its established UK channels
- ECS will receive an agreed proportion of the net sales price, providing direct exposure to UK product sell-through
- Initial product supply targeted for November 2026, subject to completion of product registrations, permits and other regulatory requirements
- Agreement has an initial two-year term, is non-exclusive and does not contain minimum purchase commitments

ECS Botanics Holdings Ltd (ASX: ECS) ("ECS" or the "Company"), a leading medicinal cannabis company, is pleased to announce that the Company has entered into a Distribution and Manufacturing Agreement with Rokshaw Limited trading as Curaleaf Laboratories, to support the launch and distribution of ECS-branded medicinal cannabis products in the United Kingdom.

The agreement expands ECS's international branded product strategy into the UK through an established pharmaceutical manufacturing and distribution partner with which ECS has maintained a long-standing commercial relationship.

Under the agreement, ECS will supply Australian-grown medicinal cannabis flower in bulk to Curaleaf Laboratories in the UK. Curaleaf Laboratories will undertake local manufacturing into ECS-branded 10g pouches in accordance with applicable EU GMP, GDP and regulatory requirements and distribute the finished products through its own and third-party distribution channels.

Initial supply is targeted for November 2026, subject to completion of product registrations, import and export permits and other applicable regulatory requirements.



Initial UK Product Portfolio

The agreement initially covers six ECS-branded Australian-grown medicinal cannabis flower products.

All products are intended to be supplied in 10g ECS-branded pouches using UK-compliant packaging and labelling.

UK Distribution Model

The agreement establishes a consignment-based commercial model under which ECS retains ownership of product until it is sold by Curaleaf Laboratories or paid for.

The agreement provides ECS with direct exposure to market sell-through while leveraging Curaleaf Laboratories' established UK manufacturing and distribution infrastructure.

Expanding ECS's International Branded Strategy

The UK agreement supports ECS's strategy of increasing the contribution of its own brands and leveraging the cultivation and manufacturing platform established in Australia to access selected international markets.

ECS's branded product strategy has become an increasingly important driver of the business, with the Company focused on capturing greater value from the products it cultivates and manufactures rather than relying predominantly on lower-margin wholesale channels.

The agreement with Curaleaf Laboratories gives ECS access to established local manufacturing, regulatory and distribution capabilities without requiring ECS to establish its own downstream infrastructure in the UK. It also broadens the Company's international offering across multiple brands.

ECS Botanics Managing Director, Nan-Maree Schoerie, said:

"Following the launch of our product brand through Nimbus in Germany, this agreement represents another important step in ECS's international growth strategy. It provides a clear pathway to introduce ECS's products into the UK market through a partner with whom we have built a long-standing commercial relationship."

"Our strategy is increasingly focused on extracting greater value from the cultivation and manufacturing platform we have built by growing our own brands and selectively expanding them into international markets."

"The structure with Curaleaf Laboratories allows ECS to retain exposure to the value generated when our products are sold in the UK, while leveraging Curaleaf's established local manufacturing and distribution infrastructure."

"This agreement gives us the opportunity to participate across different segments of the UK market with Australian-grown flower while continuing to build the value of ECS-owned and licensed brands internationally."

"Our immediate focus is now on completing the required registrations and permits, with initial supply targeted for November."



Curaleaf International UK Managing Director, Jonathan Hodgson, said:

"We're delighted to be partnering with ECS Botanics to bring their high-quality, EU-GMP products to the UK through Curaleaf Laboratories. ECS Botanics shares our commitment to quality, consistency and patient access. This partnership further strengthens our ability to support leading cannabis brands with a fully compliant UK manufacturing and distribution platform."

By combining ECS Botanics' expertise in cultivation and pharmaceutical-grade production with Curaleaf Laboratories' UK manufacturing, regulatory and supply-chain capabilities, we can deliver branded products to the UK market with the standards of quality and reliability that patients and prescribers rightly expect. We're excited to build on this partnership and continue expanding the range of EU-GMP medical cannabis products available to UK patients."

Material Contract Information

The material terms of the Distribution and Manufacturing Agreement include:

- **Parties:** ECS Botanics MC Pty Ltd and Rokshaw Limited trading as Curaleaf Laboratories.
- **Territory:** United Kingdom, including the Channel Islands and Isle of Man.
- **Appointment:** Curaleaf Laboratories is appointed as to import, market, distribute and resell the agreed ECS products in the Territory.
- **Purchase commitments:** The agreement contains no minimum purchase or revenue commitments. Product volumes and revenue will depend on market demand and sell-through. Accordingly, ECS does not consider it appropriate to provide revenue guidance at this stage.
- **Term:** The agreement has an initial term of two years and automatically renews for subsequent two-year periods unless terminated in accordance with its terms. Following the first anniversary, either party may terminate the agreement for convenience by providing at least three months' written notice.
- **Regulatory requirements:** Initial supply remains subject to completion of the required product registrations, permits and other regulatory and operational requirements.

About Curaleaf Laboratories

Curaleaf Laboratories is one of the UK-leading experts in manufacturing and distribution of EU-GMP medical cannabis. With a MHRA-approved medical cannabis manufacturing facility and a comprehensive quality management system, Curaleaf Laboratories is meeting the growing needs of healthcare professionals and patients for a consistent range of medical cannabis manufactured to EU-GMP standards, with varying novel dosage forms and levels of cannabinoid content. Curaleaf Laboratories was the first manufacturer of full spectrum medical cannabis in the UK.

Part of Curaleaf International since 2019, Curaleaf Laboratories has evolved from an established specials medicines manufacturer with over a decade of expertise in unlicensed medicines. With that experience, Curaleaf Laboratories is widening access to prescribers, clinics and pharmacies all across the UK, with a focus on innovation and collaboration, while operating as a manufacturer, distributor and partner for licensed producers and cultivators..



ECS has maintained a long-standing commercial relationship with Curaleaf Laboratories and will leverage its established UK infrastructure to support the manufacture, packing, distribution and commercialisation of ECS-branded products.

Authorised for release by Nan-Maree Schoerie, Managing Director

-ENDS-

Investors and Media

Tim Dohrmann, NWR Communications

P: +61 468 420 846

E: tim@nwrcommunications.com.au

About ECS Botanics Holdings Ltd

ECS Botanics Holdings Ltd (ASX: ECS) is an Australian medicinal cannabis cultivator and manufacturer located in Northwest Victoria. ECS utilises progressive and innovative cultivation methodologies to produce quality medicine in a sustainable way, adopting regenerative and organic horticultural practices and renewable energy sources. Licenced by the Australian Therapeutic Goods Administration to manufacture GMP (equivalent to PIC/S, EU agencies are all PIC/S members) certified products, ECS has become a leading provider of high quality, affordable medicinal cannabis.